AstraZeneca Results Presentation Deck

33 AstraZeneca PADA AstraZeneca: the next chapter Industry-leading growth, best-in-class innovative pipeline Double-digit CAGR through 2025 |DGO Longer-term growth fueled by existing portfolio and new innovative medicines Differentiated, durable portfolio Attractive LOE profile, unrivalled R&D productivity and pipeline Financial execution % Continued focus on operating leverage and cash generation Reinvestment in our main disease areas High-growth pipeline opportunities, value-enhancing business development B

View entire presentation